Estimating the Nasdaq listing price for Anteris Technologies (AMEUF) involves several variables, but a reasonable starting point can be inferred based on:
1. Current OTC Price: The stock is trading at $8 USD on the OTC market. Companies often price their IPO slightly above the prevailing OTC market price to reflect increased visibility, liquidity, and institutional investor access.
2. Comparable Listings: OTC stocks that move to Nasdaq often see a 15-50% price uplift depending on demand, market sentiment, and company fundamentals. For Anteris, which is focused on innovative heart technologies, the demand from biotech-focused investors could be strong.
3. Market Sentiment: If the market perceives Anteris' technologies (like DurAVR™) as groundbreaking, the IPO price could be set higher by underwriters.
Estimated IPO Range:
Conservative Estimate: $9–$10 USD
Optimistic Estimate: $10–$12 USD
These estimates assume moderate to high demand during the IPO process and stable market conditions.
An exact number will be announced by Anteris and its underwriters closer to the IPO date. It’s worth monitoring their communications for final pricing details.
(20min delay)